A Mitochondrial Plasma Proteomic Signature Identifies Metastatic Chromophobe Renal Cell Carcinoma
Cancers · 23.03.2026 · 18 (6) · 1032
DOI: 10.3390/cancers18061032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 23.03.2026. Verfasst von Clara Steiner und 15 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Boston, MA 02215, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: KCCure Chromophobe Kidney Cancer Research Grant, Tuttle Fund for Chromophobe RCC Research, CDMRP.
Abstract (Originalsprache)
Background
Chromophobe renal cell carcinoma (ChRCC) is characterized by the accumulation of abnormal mitochondria, a high rate of mitochondrial DNA (mtDNA) mutations, and altered oxidative metabolism. There are no existing circulating biomarkers to distinguish metastatic ChRCC from clear cell renal cell carcinoma (ccRCC).
Methods
High-throughput plasma proteomic profiling using the SomaScan platform was performed in 18 ChRCC (including 16 metastatic ChRCC) and 197 metastatic ccRCC patients. Data were harmonized to generate a unified 7K-protein matrix.
Results
Differential expression analysis was performed using limma (version 3.62.2). Of 7272 quantified human plasma proteins, 209 were differentially expressed between ChRCC and ccRCC. Upregulated proteins in ChRCC included essential β-oxidation enzymes such as ECH1 (enoyl-CoA hydratase 1) and ECI1 (enoyl-CoA delta-isomerase 1), suggesting increased long-chain fatty acid degradation. Creatine and energy-buffering pathways were also represented, with increased CKMT1A (Creatine Kinase, Mitochondrial 1A) in ChRCC. KIM-1 (Kidney Injury Molecule-1) and leptin were lower in ChRCC, consistent with the known upregulation of these proteins in ccRCC. Pathway enrichment analyses revealed an overrepresentation of mitochondrial protein degradation, fatty acid β-oxidation, and respiratory electron transport in ChRCC, suggesting that ChRCC sheds a unique mitochondrial signature into the peripheral circulation. A bootstrap-based LASSO logistic regression restricted to upregulated mitochondrial proteins in ChRCC vs. ccRCC consistently selected ECI1 and CKMT1A. The LASSO model achieved an AUROC of 0.964.
Conclusions
Compared to ccRCC, the plasma proteome of metastatic ChRCC is dominated by mitochondrial metabolic enzymes, revealing a systemic metabolic phenotype strikingly aligned with the known histologic accumulation of abnormal mitochondria in ChRCC cells.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Dana-Farber Cancer Institute, Boston, MA 02215, USA.
- Department of Urology, University Hospital Leipzig, 04103 Leipzig, Germany.
- Brigham and Women's Hospital, Boston, MA 02115, USA.
- Henry Ford Hospital, Detroit, MI 48202, USA.
- Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
- Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT 84132, USA.
ORCID-Profile: Clara Steiner, Jessica F Williams, Vinay K Giri, Liliana Ascione, Toni K Choueiri, Wenxin Xu
Förderung
- KCCure Chromophobe Kidney Cancer Research Grant
- Tuttle Fund for Chromophobe RCC Research
- CDMRP
- Dana-Farber/Harvard Cancer Center Kidney SPORE
- Kohlberg Chair at Harvard Medical School Fund
- Trust Family Fund
- Michael Brigham Fund
- Pan Mass Challenge Fund
Zitieren
APA
Steiner, C., Han, T., Safi, S., Bzeih, W., Mansour, H., Saad, E., Williams, J. F., Hirsch, M. S., Giri, V. K., Ascione, L., Elon, Y., Dicker, A. P., Tang, Y., Choueiri, T. K., Henske, E. P., & Xu, W. (2026). A Mitochondrial Plasma Proteomic Signature Identifies Metastatic Chromophobe Renal Cell Carcinoma. Cancers, 18(6), 1032. https://doi.org/10.3390/cancers18061032
Vancouver
Steiner C, Han T, Safi S, Bzeih W, Mansour H, Saad E, et al. A Mitochondrial Plasma Proteomic Signature Identifies Metastatic Chromophobe Renal Cell Carcinoma. Cancers. 2026;18(6):1032. doi:10.3390/cancers18061032
BibTeX
@article{Steiner2026,
author = {Steiner, Clara and Han, Tiegang and Safi, Steven and Bzeih, Wafaa and Mansour, Hadi and Saad, Eddy and Williams, Jessica F and Hirsch, Michelle S and Giri, Vinay K and Ascione, Liliana and Elon, Yehonatan and Dicker, Adam P and Tang, Yan and Choueiri, Toni K and Henske, Elizabeth P and Xu, Wenxin},
title = {A Mitochondrial Plasma Proteomic Signature Identifies Metastatic Chromophobe Renal Cell Carcinoma},
journal = {Cancers},
year = {2026},
volume = {18},
number = {6},
pages = {1032},
doi = {10.3390/cancers18061032}
}
EUVIMED